The €8.6M grant has been awarded to the SHIGETECVAX project, an international consortium of world-leading vaccine organizations - The European Vaccine Initiative (consortium leader), EveliQure Biotechnologies, University of Gothenburg, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b) and PATH.
The project will run for 5 years and will cover the manufacture and formulation of clinical trial material and Phase 1 safety and immunogenicity studies in two different populations, adults in Europe and children in Bangladesh.
Read full story.